Nektar Therapeutics (NASDAQ:NKTR) Expected to Earn Q4 2024 Earnings of ($0.26) Per Share

Nektar Therapeutics (NASDAQ:NKTR) – Equities research analysts at Zacks Research raised their Q4 2024 EPS estimates for shares of Nektar Therapeutics in a report released on Tuesday, August 6th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter, up from their prior forecast of ($0.27). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.84) per share.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03. The firm had revenue of $21.64 million for the quarter, compared to the consensus estimate of $14.91 million. Nektar Therapeutics had a negative net margin of 195.02% and a negative return on equity of 107.31%. During the same period last year, the company posted ($0.25) EPS.

Separately, Rodman & Renshaw initiated coverage on shares of Nektar Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $2.00 target price for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Nektar Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $1.50.

Nektar Therapeutics Price Performance

Shares of NKTR traded down $0.10 during mid-day trading on Thursday, hitting $1.11. 1,130,121 shares of the company’s stock were exchanged, compared to its average volume of 1,991,905. Nektar Therapeutics has a 52 week low of $0.41 and a 52 week high of $1.93. The company has a 50-day simple moving average of $1.28 and a 200 day simple moving average of $1.16. The company has a market cap of $204.26 million, a PE ratio of -1.21 and a beta of 0.66.

Hedge Funds Weigh In On Nektar Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. bought a new position in shares of Nektar Therapeutics during the 2nd quarter worth approximately $29,000. Values First Advisors Inc. bought a new position in Nektar Therapeutics during the 2nd quarter valued at $56,000. State Board of Administration of Florida Retirement System bought a new position in Nektar Therapeutics during the 1st quarter valued at $63,000. SG Americas Securities LLC lifted its stake in Nektar Therapeutics by 63.0% during the 2nd quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock valued at $91,000 after acquiring an additional 28,338 shares in the last quarter. Finally, Mackenzie Financial Corp bought a new position in Nektar Therapeutics during the 4th quarter valued at $42,000. 75.88% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Nektar Therapeutics

In other news, CEO Howard W. Robin sold 16,650 shares of the business’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $1.75, for a total transaction of $29,137.50. Following the sale, the chief executive officer now directly owns 863,239 shares in the company, valued at $1,510,668.25. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 43,505 shares of company stock worth $65,409 over the last 90 days. Insiders own 3.71% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.